Seeking Partner for our New COVID19 Therapy
Ibex Biosciences is seeking a partnership or license to our VHH against CD147 (also known as Basigin, EMMPRIN, Neurothelin), with target indications that include cancer, immune disorders, and infectious diseases (particularly COVID-19 and malaria). CD147 has also been reported to be a alternative receptor for infection by coronavirus,1,2 and malaria.3 Targeting of host receptor rather than the pathogen antigen avoids issues concerning pathogen mutations that can decrease treatment or vaccine efficacy. In addition, a clinical trial using a humanized anti-CD147 antibody has been reported to benefit COVID-19 patients4 and other studies point to the safety of anti-CD147 antibodies.
Ibex Biosciences, LLC ("Ibex") is a Delaware Limited Liability Company headquartered in Cumberland, Maryland. Unique to many early-stage biotechnology companies, Ibex engages in a diverse approach to research and development. Ibex strives to discover, validate, and produce potential solutions to a multitude of serious challenges facing human and ecological health by investing in exploratory projects and processes that may not have been validated within the public research community.
Ibex is willing to take significant risk to fulfill its mission which is the relentless pursuit to effectively treat a vast number of unmet medical conditions plaguing humanity.
Research & Development
Ibex Announces New Patent
August 8, 2019
Ibex announces the patent publication of a Gene Therapy to be used in the treatment of various cancers.
Ibex Announces SBIR Award
September 20, 2017
Ibex has been awarded an SBIR phase 1 for the further development of its anti-MIF antibodies.
Ibex has a portfolio of therapeutic antibodies, gene therapy and stem cell programs. Additionally, Ibex is developing diagnostic antibodies for IHC to increase the diagnostic reliability of biopsies.